These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32613551)

  • 1. First approval of generic dry powder inhaler drug products in Japan.
    Kuribayashi R; Myoenzono A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1517-1519. PubMed ID: 32613551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan.
    Kuribayashi R; Myoenzono A; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):743-745. PubMed ID: 31062276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic Drug Product Development in Japan: Regulatory Updates During 2014-2019 and the Future.
    Kasuga M; Kuribayashi R; Ogawa T; Ugi A; Yamaguchi T; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):711-719. PubMed ID: 34586614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Approval of Generic Mometasone Furoate Nasal Suspension Spray in Japan: Similarities and Differences Between Japan and the USA.
    Kuribayashi R; Kasuga M; Kuwana K; Yamaguchi T
    Ther Innov Regul Sci; 2023 Mar; 57(2):173-177. PubMed ID: 36100793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
    Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective.
    Newman B; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Spagnola M; Walenga RL; Wang Z; Zhao L; El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK
    Adv Drug Deliv Rev; 2022 Nov; 190():114526. PubMed ID: 36067967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
    Kuribayashi R; Yamaguchi T; Takagi K
    Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Bioequivalence Between the New Procaterol Hydrochloride Hydrate Dry Powder Inhaler and the Approved Dry Powder Inhaler in Patients With Asthma in a Randomized, Double-Blind, Double-Dummy, Crossover Comparison Study: A Phase 3 Study.
    Shirai R; Suzaki Y; Sato K; Takeuchi Y; Tokimatsu I; Koga N; Kadota J; Ohashi K
    Clin Pharmacol Drug Dev; 2018 May; 7(4):392-399. PubMed ID: 28884969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspective.
    El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Newman B; Spagnola M; Walenga RL; Zhao L
    Adv Drug Deliv Rev; 2022 Oct; 189():114519. PubMed ID: 36038083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.
    Komase Y; Asako A; Kobayashi A; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1365-75. PubMed ID: 25525354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Perceptions of Switching to a Generic Dry Powder Inhaler - Increased Understanding Through Journey Mapping.
    Ray SE; Boudewyns V; Davis C; Tzeng JP; Srivastava I; Oguntimein O; Conti DS; Feibus KB
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1751-1768. PubMed ID: 35965841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness.
    Tashkin DP; Koltun A; Wallace R
    Allergy Asthma Proc; 2021 Jan; 42(1):30-35. PubMed ID: 33353582
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
    Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
    Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?
    Benet LZ; Jayachandran P; Carroll KJ; Burmeister Getz E
    Clin Pharmacol Ther; 2019 Feb; 105(2):326-328. PubMed ID: 30652313
    [No Abstract]   [Full Text] [Related]  

  • 17. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA.
    Fernandes SD; Koland M
    Ther Innov Regul Sci; 2020 Jul; 54(4):738-748. PubMed ID: 32557296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
    Mehta R; Moore A; Riddell K; Joshi S; Chan R
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.